Glissmann, head of asset allocation research at Goldman Sachs, on the outperformance of European and Chinese stocks over the ...

Investors might be surprised to learn that in the past five years, shares of Goldman Sachs (NYSE: GS) have soared 186%.

There's no question the financial services industry is home to some of the world's most dominant businesses. One such company ...

Palantir Technologies (PLTR) has been among the best-performing stocks over the past 12 months, driven by improving earnings, ...

Investors might be surprised to learn that in the past five years, shares of Goldman Sachs (NYSE: GS) have soared 186%. Including the company's dividend, the total return achieved was 219%.

Expectations of a banner year in dealmaking have not yet materialized due to worries about inflation and uncertainties over U ...

See what positions big money is taking on your favorite stocks. Click here for access. * An analyst from Wells Fargo persists with their Overweight rating on Goldman Sachs Gr, maintaining a target ...

Today's Research Daily features new research reports on 16 major stocks, including The Goldman Sachs Group, Inc. (GS), The Progressive Corp. (PGR) and Boston Scientific Corp. (BSX), as well as ...

Super Micro may also face margin pressures as it focuses on share gains. Customer concentration risks and prior financial ...

See what positions big money is taking on your favorite stocks. Click here for access. * An analyst from Wells Fargo has decided to maintain their Overweight rating on Goldman Sachs Gr ...

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Free Report) shares reached a new 52-week low on Monday after The Goldman Sachs Group lowered their price target on the stock from $29.00 to $15.00. The ...

Arcutis Biotherapeutics (NASDAQ:ARQT – Free Report) had its price objective hoisted by The Goldman Sachs Group from $13.00 to ...